Product Detail

1 3

Disclaimer

Research Use Only - Important Disclaimer.

All products listed and sold by Peptides Vela are intended STRICTLY for laboratory research purposes — specifically for in vitro studies. They are NOT INTENDED for human or animal consumption, NOR FOR USE in foods, drugs, cosmetics, medical devices, or diagnostic procedures.

Posologie - IMPORTANT.

The information and materials provided on this website are for educational and informational purposes ONLY.

Listing a product on this website DOES NOT grant a license to use it in any way that may infringe on patents or VIOLATE LAWS.

Cagrilintide 5mg

Name: Cagrilintide 5mg
Brand: Peptides Vela
Price: 135.00 USD
Availability: InStock

$135.00 USD

Sale Exhausted

Shipping calculated at checkout.

Free Shipping From $150
Next Day Shipping
Secure Payement & Returns Up To 30 Days

Other Sizes

Quantity

Buy 3 and save 5%
Buy 5 and save 7%
Buy 10 and save 9%

View full details

Name	Cagrilintide 5mg
Purity	>99%
Molecular Formula	C₁₉₄H₃₁₂N₅₄O₅₉S₂.H₄O₂
Molecular Weight	4409.01 g/mol
Appearance	White to off-white lyophilized powder
Storage Conditions	2–8°C, protected from light

Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in conjunction with insulin. Cagrilintide has shown promise in animal trials as a treatment for obesity and type 2 diabetes.

It has been studied for benefits not just in type 2 diabetes, but for liver damage, alcohol-related liver disease, and heart/blood vessel disease.

There is some speculation about the role of this peptide in Alzheimer’s disease as well, but no research has been published in that particular sub-domain, yet. Many trials, however, have looked at the combination of cagrilintide and semaglutide in the treatment of obesity and type 2 diabetes. The two proteins appear to work synergistically to provide more robust and more permanent weight loss effects. It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited.

Further research needs to be done to determine the efficacy and safety profiles.